[Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity

Rhea-AI Filing Summary

PTC Therapeutics, Inc. (PTCT) reported insider activity by its Chief Technical Operations Officer. On 11/24/2025, the executive exercised several stock options to buy common stock at exercise prices of $18.01 and $33.02 per share and, on the same date, sold corresponding shares of common stock in multiple transactions at weighted average prices around $80 per share, with specific ranges disclosed for each sale.

The transactions were carried out under a written Rule 10b5-1 trading plan adopted on December 10, 2024, which is intended to provide an affirmative defense for pre-planned trades. Following the reported transactions, the executive beneficially owned 100,625 shares of PTCT common stock directly and an additional 6,179 shares indirectly through a spouse. Certain stock options reported in the filing are noted as currently exercisable, with stated expiration dates in 2028 and 2029.

Insider Trade Summary

Exercise and Sale: 35,572 shares ($1.78M approx. pre-tax spread)

Exercise and Sale 16 txns

Insider Almstead Neil Gregory

Role CHIEF TECHNICAL OPS OFFICER

Sold 35,572 shs ($2.85M)

Approx. gross sale proceeds $2.85M

Approx. exercise cost $1.08M

Approx. pre-tax spread $1.78M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	1,900	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	1,650	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	4,715	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	21,206	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	6,101	$0.00	$0.00
Exercise	Common Stock	1,900	$18.01	$34K
Sale	Common Stock	1,900	$80.14	$152K
Exercise	Common Stock	1,650	$33.02	$54K
Sale	Common Stock	1,650	$80.14	$132K
Exercise	Common Stock	4,715	$18.01	$85K
Sale	Common Stock	4,715	$80.15	$378K
Exercise	Common Stock	21,206	$33.02	$700K
Sale	Common Stock	21,206	$80.19	$1.70M
Exercise	Common Stock	6,101	$33.02	$201K
Sale	Common Stock	6,101	$80.17	$489K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 71,928 shares (Direct); Common Stock — 100,625 shares (Direct); Common Stock — 6,179 shares (Indirect, By Spouse)

Footnotes (7)

1. F1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024.
2. F2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.55 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
3. F3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.14 to $80.48 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
4. F4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.68 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
5. F5. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
6. F6. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.56 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
7. F7. Currently exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/26/2025 - 05:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Almstead Neil Gregory

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF TECHNICAL OPS OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/24/2025		M(1)		1,900	A	$18.01	102,525	D
Common Stock	11/24/2025		S(1)		1,900	D	$80.14(2)	100,625	D
Common Stock	11/24/2025		M(1)		1,650	A	$33.02	102,275	D
Common Stock	11/24/2025		S(1)		1,650	D	$80.14(3)	100,625	D
Common Stock	11/24/2025		M(1)		4,715	A	$18.01	105,340	D
Common Stock	11/24/2025		S(1)		4,715	D	$80.15(4)	100,625	D
Common Stock	11/24/2025		M(1)		21,206	A	$33.02	121,831	D
Common Stock	11/24/2025		S(1)		21,206	D	$80.19(5)	100,625	D
Common Stock	11/24/2025		M(1)		6,101	A	$33.02	106,726	D
Common Stock	11/24/2025		S(1)		6,101	D	$80.17(6)	100,625	D
Common Stock								6,179	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$18.01	11/24/2025		M(1)			1,900	(7)	01/02/2028	Common Stock	1,900	$0	15,600	D
Stock Option (Right to Buy)	$33.02	11/24/2025		M(1)			1,650	(7)	01/21/2029	Common Stock	1,650	$0	70,850	D
Stock Option (Right to Buy)	$18.01	11/24/2025		M(1)			4,715	(7)	01/02/2028	Common Stock	4,715	$0	10,885	D
Stock Option (Right to Buy)	$33.02	11/24/2025		M(1)			21,206	(7)	01/21/2029	Common Stock	21,206	$0	49,644	D
Stock Option (Right to Buy)	$33.02	11/24/2025		M(1)			6,101	(7)	01/21/2029	Common Stock	6,101	$0	11,399	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024.

2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.55 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.14 to $80.48 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.68 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

5. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

6. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.56 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

7. Currently exercisable.

	/s/ Avraham S. Adler, Attorney-in-Fact	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.